Fwd: Early Test for Cancer Isn?t Always Best Course (New York Times)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Aug 11, 2008 at 11:36 PM
Subject: Early Test for Cancer Isn?t Always Best Course (New York Times)
To: mesothelioma77@gmail.com


Is finding cancer early always better?

Tue, 12 Aug 2008 00:32:30 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11ourbivs/*http%3A//www.nytimes.com/2008/08/12/health/12well.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.
To: mesothelioma77@gmail.com


[1]Curr Pharm Biotechnol. 2008 Jun; 9(3): 231-4
Krauss J, Arndt MA, Dübel S, Rybak SM

Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models and cancer patients. Ranpirnase (Onconase), the first ribonuclease being evaluated as a therapeutic in humans, has progressed to phase III clinical trials in patients with unresectable mesothelioma. Conjugation of RNases to internalizing tumor-targeting monoclonal antibodies was shown to enhance specific cell killing by several orders of magnitude both in vitro and in animal models. In this review we describe the development and current status of genetically engineered 2(nd) generation immunoRNases as promising novel anti-cancer therapeutics.



___
Source: http://www.hubmed.org/display.cgi?uids=18673289
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc